Inactive Ingredient Search for Approved Drug Products
You are Searching: Change and Deletion by Inactive Ingredient Name Beginning with G
| Quarter | Inactive Ingredient | Route of Administration | Dosage Form | Maximum Potency per unit dose | Maximum Daily Exposure | Status | |
|---|---|---|---|---|---|---|---|
| Q2 2022 | GLYCERIN | NASAL | SPRAY, METERED | 13mg | Correction | ||
| Q3 2022 | GLYCERIN | NASAL | SPRAY, METERED | 13mg | Correction | ||
| Q2 2022 | GELATIN | SUBLINGUAL | TABLET, ORALLY DISINTEGRATING | 12.50 mg | MDE Replacement | ||
| Q3 2022 | GELATIN | SUBLINGUAL | TABLET, ORALLY DISINTEGRATING | 13mg | MDE Replacement | ||
| Q2 2022 | GLYCERIN | ORAL | PASTE | 127.40 mg/ 1.00 ml | MDE Replacement | ||
| Q3 2022 | GLYCERIN | ORAL | PASTE | 3822mg | MDE Replacement | ||
| Q2 2022 | GLYCERIN | TOPICAL | CREAM, AUGMENTED | 4.00 %w/w | MDE Replacement | ||
| Q3 2022 | GLYCERIN | TOPICAL | CREAM, AUGMENTED | 55mg | MDE Replacement | ||
| Q2 2022 | GUAR GUM | ORAL | TABLET, EXTENDED RELEASE | 24.00 mg | MDE Replacement | ||
| Q3 2022 | GUAR GUM | ORAL | TABLET, EXTENDED RELEASE | 24mg | MDE Replacement |
FDA/Center for Drug Evaluation and Research
Office of Pharmaceutical Quality
Office of Policy for Pharmaceutical Quality
Mailbox for IID corrections IIDUpdate@fda.hhs.gov
Update Frequency: Quarterly
Data Through: July 1, 2022
Database Last Updated: July 18, 2022